Study in mice found transient microglial depletion, or chemokine receptor blockade, resolved immunotherapy-related cognitive impairment.

UK-based Leucid Bio has dosed the first subject in the multi-centre Phase I AERIAL trial of autologous lateral chimeric ...

Second of 2 parts featuring an interview with Stephen Strickland, MD, MSCI,director, Leukemia Research for Sarah Cannon ...

Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionised cancer treatment, especially for aggressive and ...

Our trial provides proof of concept that cytokine-armored CAR T-cell treatment is feasible and may enhance antitumor activity without additional toxic effects,” researchers reported.

After treatment with CAR-T cells - immune cells engineered to attack cancer - patients sometimes tell their doctors they feel like they have "brain fog," or forgetfulness and difficulty concentrating.

Leucid Bio has dosed the first patient in its Phase 1 AERIAL trial of LEU011, an NKG2D-targeting CAR-T therapy for solid ...

Once prostate cancer no longer responds to hormonal therapy, the cancer is called castration-resistant. Find out which ...

Cancer treatment with a cell-based immunotherapy causes mild cognitive impairment, a Stanford Medicine team found. They also identified compounds that could treat it.

Swedish cancer patients treated with CAR T-cell therapy show better survival rates and fewer side effects than seen in ...